医学影像预测肝细胞癌治疗后复发的研究进展
Research Progress of Medical Imaging Predictions of HCC Recurrence after Treatment
DOI: 10.12677/acm.2024.14102706, PDF,    科研立项经费支持
作者: 于 凌, 王志强*:北华大学附属医院医学影像科,吉林 吉林
关键词: 肝细胞癌医学影像学治疗复发Hepatocellular Carcinoma Medical Imaging Treatment Recrudescence
摘要: 肝细胞癌是世界上第六大最常见的癌症,由于其发病率不断上升,它已成为普通人群中癌症相关死亡的第三大原因。尽管肝细胞癌患者的治疗不断改进,但术后复发率仍不断上升。因此,早期诊断肝细胞癌的复发并给予相应的个体化治疗成为目前提高肝细胞癌患者生存率的重点。目前肝癌是唯一无需病理诊断,仅通过影像学手段即可确诊的实体肿瘤。无创的影像学检查方法,在肝癌的诊断、分期、疗效评价及预后等中发挥了重要作用。随着影像学检查的精准化发展,也提升了肝癌患者整体的生存率。该篇综述旨在讨论医学影像预测肝细胞癌治疗后复发的研究进展。
Abstract: Hepatocellular carcinoma is the sixth most common cancer in the world. Because of its rising incidence rate, it has become the third leading cause of cancer-related deaths in the general population. Despite continuous improvement in the treatment of hepatocellular carcinoma patients, the postoperative recurrence rate continues to rise. Therefore, early diagnosis of hepatocellular carcinoma recurrence and corresponding personalized treatment have become the focus of improving the survival rate of hepatocellular carcinoma patients. At present, liver cancer is the only solid tumor that can be diagnosed through imaging methods without pathological diagnosis. The non-invasive imaging examination method has played an important role in the diagnosis, staging, efficacy evaluation, and prognosis of liver cancer. With the development of precise imaging examinations, the overall survival rate of liver cancer patients has also been improved. This review aims to discuss the research progress of medical imaging in predicting the recurrence of hepatocellular carcinoma after treatment.
文章引用:于凌, 王志强. 医学影像预测肝细胞癌治疗后复发的研究进展[J]. 临床医学进展, 2024, 14(10): 632-639. https://doi.org/10.12677/acm.2024.14102706

参考文献

[1] 庄琰, 杜森, 张进, 等. 基于MRI影像学指标分析影响原发性肝癌患者预后的危险因素及验证模型构建[J]. 中国CT和MRI杂志, 2023, 21(7): 100-102.
[2] Konyn, P., Ahmed, A. and Kim, D. (2021) Current Epidemiology in Hepatocellular Carcinoma. Expert Review of Gastroenterology & Hepatology, 15, 1295-1307. [Google Scholar] [CrossRef] [PubMed]
[3] Elsayes, K.M., et al. (2019) LI-RADS: A Conceptual and Historical Review from Its Beginning to Its Recent Integration into AASLD Clinical Practice Guidance. Journal of Hepatocellular Carcinoma, 6, 49-69.
[4] Ivanics, T., Murillo Perez, C.F., Claasen, M.P.A.W., Patel, M.S., Morgenshtern, G., Erdman, L., et al. (2022) Dynamic Risk Profiling of HCC Recurrence after Curative Intent Liver Resection. Hepatology, 76, 1291-1301. [Google Scholar] [CrossRef] [PubMed]
[5] Wu, W., Klockow, J.L., Mohanty, S., Ku, K.S., Aghighi, M., Melemenidis, S., et al. (2019) Theranostic Nanoparticles Enhance the Response of Glioblastomas to Radiation. Nanotheranostics, 3, 299-310. [Google Scholar] [CrossRef] [PubMed]
[6] 胡维娟, 王迪, 吕蓉. CT/MRI LI-RADS在肝细胞癌高风险人群中的应用和新进展[J]. 临床放射学杂志, 2023, 42(3): 514-518.
[7] Couri, T. and Pillai, A. (2019) Goals and Targets for Personalized Therapy for HCC. Hepatology International, 13, 125-137. [Google Scholar] [CrossRef] [PubMed]
[8] Vitale, A., Saracino, E., Boccagni, P., Brolese, A., D’Amico, F., Gringeri, E., et al. (2009) Validation of the BCLC Prognostic System in Surgical Hepatocellular Cancer Patients. Transplantation Proceedings, 41, 1260-1263. [Google Scholar] [CrossRef] [PubMed]
[9] Reig, M., et al. (2021) BCLC Strategy for Prognosis Prediction and Treatment Recommendation Barcelona Clinic Liver Cancer (BCLC) Staging System: The 2022 Update. Journal of Hepatology, 76, 681-693.
[10] Tan, D.J.H., Wong, C., Ng, C.H., Poh, C.W., Jain, S.R., Huang, D.Q., et al. (2021) A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, α-Fetoprotein, Income and Ethnicity. Journal of Clinical Medicine, 10, Article 238. [Google Scholar] [CrossRef] [PubMed]
[11] Galle, P.R., Forner, A., Llovet, J.M., Mazzaferro, V., Piscaglia, F., Raoul, J., et al. (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236. [Google Scholar] [CrossRef] [PubMed]
[12] Akateh, C., Black, S.M., Conteh, L., Miller, E.D., Noonan, A., Elliott, E., et al. (2019) Neoadjuvant and Adjuvant Treatment Strategies for Hepatocellular Carcinoma. World Journal of Gastroenterology, 25, 3704-3721. [Google Scholar] [CrossRef] [PubMed]
[13] Marrero, J.A., Kulik, L.M., Sirlin, C.B., Zhu, A.X., Finn, R.S., Abecassis, M.M., et al. (2019) Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Clinical Liver Disease, 13, 1. [Google Scholar] [CrossRef
[14] Santopaolo, F., Lenci, I., Milana, M., Manzia, T.M. and Baiocchi, L. (2019) Liver Transplantation for Hepatocellular Carcinoma: Where Do We Stand? World Journal of Gastroenterology, 25, 2591-2602. [Google Scholar] [CrossRef] [PubMed]
[15] Mazzaferro, V., Citterio, D., Bhoori, S., Bongini, M., Miceli, R., De Carlis, L., et al. (2020) Liver Transplantation in Hepatocellular Carcinoma after Tumour Downstaging (XXL): A Randomised, Controlled, Phase 2b/3 Trial. The Lancet Oncology, 21, 947-956. [Google Scholar] [CrossRef] [PubMed]
[16] Cucchetti, A., Zhong, J., Berhane, S., Toyoda, H., Shi, K., Tada, T., et al. (2020) The Chances of Hepatic Resection Curing Hepatocellular Carcinoma. Journal of Hepatology, 72, 711-717. [Google Scholar] [CrossRef] [PubMed]
[17] Orcutt, S.T. and Anaya, D.A. (2018) Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control, 25. [Google Scholar] [CrossRef] [PubMed]
[18] Bruix, J., Gores, G.J. and Mazzaferro, V. (2014) Hepatocellular Carcinoma: Clinical Frontiers and Perspectives. Gut, 63, 844-855. [Google Scholar] [CrossRef] [PubMed]
[19] Lencioni, R., de Baere, T., Soulen, M.C., Rilling, W.S. and Geschwind, J.H. (2016) Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review of Efficacy and Safety Data. Hepatology, 64, 106-116. [Google Scholar] [CrossRef] [PubMed]
[20] Tai, D., Loke, K., Gogna, A., Kaya, N.A., Tan, S.H., Hennedige, T., et al. (2021) Radioembolisation with Y90-Resin Microspheres Followed by Nivolumab for Advanced Hepatocellular Carcinoma (CA 209-678): A Single Arm, Single Centre, Phase 2 Trial. The Lancet Gastroenterology & Hepatology, 6, 1025-1035. [Google Scholar] [CrossRef] [PubMed]
[21] Li, J., Su, T., Gong, W., Zhong, J., Yan, L., Zhang, J., et al. (2022) Combining Stereotactic Body Radiotherapy with Camrelizumab for Unresectable Hepatocellular Carcinoma: A Single-Arm Trial. Hepatology International, 16, 1179-1187. [Google Scholar] [CrossRef] [PubMed]
[22] Tabrizian, P., Abdelrahim, M. and Schwartz, M. (2024) Immunotherapy and Transplantation for Hepatocellular Carcinoma. Journal of Hepatology, 80, 822-825. [Google Scholar] [CrossRef] [PubMed]
[23] Jung, S., Kim, J.M., Choi, G., Kwon, C.H.D., Yi, N., Lee, K., et al. (2019) Characteristics of Early Recurrence after Curative Liver Resection for Solitary Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 23, 304-311. [Google Scholar] [CrossRef] [PubMed]
[24] Zhu, Y., Gu, L., Chen, T., Zheng, G., Ye, C. and Jia, W. (2020) Factors Influencing Early Recurrence of Hepatocellular Carcinoma after Curative Resection. Journal of International Medical Research, 48. [Google Scholar] [CrossRef] [PubMed]
[25] Marasco, G., Colecchia, A., Colli, A., Ravaioli, F., Casazza, G., Bacchi Reggiani, M.L., et al. (2019) Reply to Correspondence Concerning: “Role of Liver and Spleen Stiffness in Predicting the Recurrence of Hepatocellular Carcinoma after Resection”. Journal of Hepatology, 70, 809-810. [Google Scholar] [CrossRef] [PubMed]
[26] Roayaie, S., Blume, I.N., Thung, S.N., Guido, M., Fiel, M., Hiotis, S., et al. (2009) A System of Classifying Microvascular Invasion to Predict Outcome after Resection in Patients with Hepatocellular Carcinoma. Gastroenterology, 137, 850-855. [Google Scholar] [CrossRef] [PubMed]
[27] Zhou, L., Rui, J., Zhou, W., Wang, S., Chen, S. and Qu, Q. (2017) Edmondson-Steiner Grade: A Crucial Predictor of Recurrence and Survival in Hepatocellular Carcinoma without Microvascular Invasio. PathologyResearch and Practice, 213, 824-830. [Google Scholar] [CrossRef] [PubMed]
[28] Fang, T.D., Long, G., Mi, X.Y., et al. (2022) Splenic Volume, an Easy-To-Use Predictor of HCC Late Recurrence for HCC Patients after Hepatectomy. Frontiers in Oncology, 12, Article 876668.
[29] Xu, X., Yu, J., Li, J., Sun, L., Zhang, H., Wang, M., et al. (2018) Risk Factors, Patterns, and Outcomes of Late Recurrence after Liver Resection for Hepatocellular Carcinoma: A Multicenter Cohort Study in 734 Patients over 15 Years. Journal of Clinical Oncology, 36, e16108. [Google Scholar] [CrossRef
[30] 王琦, 翟琪琪, 徐珂. CT和MRI对原发性肝癌TACE术后残留及新发病灶的诊断价值[J]. 中国CT和MRI杂志, 2023, 21(6): 107-109.
[31] 杨洁, 李秋实, 赵森, 等. MRI动态增强扫描在肝癌诊断、病理分级评估中的应用观察[J]. 中国CT和MRI杂志, 2023, 21(6): 100-102.
[32] 林丽滢, 张坤, 沈文. 肝细胞癌经导管动脉化疗栓塞术后疗效预测的影像学研究进展[J]. 国际医学放射学杂志, 2023, 46(6): 691-695.
[33] 袁恩雨, 宋彬. 肝癌影像组学的临床应用: 现状与展望[J]. 放射学实践, 2023, 38(9): 1084-1088.
[34] Du, M., Chen, L., Zhao, J., Tian, F., Zeng, H., Tan, Y., et al. (2014) Microvascular Invasion (MVI) Is a Poorer Prognostic Predictor for Small Hepatocellular Carcinoma. BMC Cancer, 14, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[35] Zhong, X., Long, H., Su, L., Zheng, R., Wang, W., Duan, Y., et al. (2022) Radiomics Models for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Abdominal Radiology, 47, 2071-2088. [Google Scholar] [CrossRef] [PubMed]
[36] Xu, X., Zhang, H., Liu, Q., Sun, S., Zhang, J., Zhu, F., et al. (2019) Radiomic Analysis of Contrast-Enhanced CT Predicts Microvascular Invasion and Outcome in Hepatocellular Carcinoma. Journal of Hepatology, 70, 1133-1144. [Google Scholar] [CrossRef] [PubMed]
[37] Zhou, Y., He, L., Huang, Y., Chen, S., Wu, P., Ye, W., et al. (2017) CT-Based Radiomics Signature: A Potential Biomarker for Preoperative Prediction of Early Recurrence in Hepatocellular Carcinoma. Abdominal Radiology, 42, 1695-1704. [Google Scholar] [CrossRef] [PubMed]
[38] Ni, M., Zhou, X., Lv, Q., Li, Z., Gao, Y., Tan, Y., et al. (2019) Radiomics Models for Diagnosing Microvascular Invasion in Hepatocellular Carcinoma: Which Model Is the Best Model? Cancer Imaging, 19, Article No. 60. [Google Scholar] [CrossRef] [PubMed]
[39] van Timmeren, J.E., Cester, D., Tanadini-Lang, S., Alkadhi, H. and Baessler, B. (2020) Radiomics in Medical Imaging—“How-To” Guide and Critical Reflection. Insights into Imaging, 11, 91. [Google Scholar] [CrossRef] [PubMed]
[40] Horvat, N., Miranda, J., El Homsi, M., Peoples, J.J., Long, N.M., Simpson, A.L., et al. (2021) A Primer on Texture Analysis in Abdominal Radiology. Abdominal Radiology, 47, 2972-2985. [Google Scholar] [CrossRef] [PubMed]